What is Global Angiotensin II Receptor Blockers Market?
The Global Angiotensin II Receptor Blockers Market is a vast and dynamic sector that encompasses a range of pharmaceutical products designed to inhibit the action of Angiotensin II, a hormone that causes blood vessels to constrict. These blockers, also known as ARBs, are primarily used in the treatment of hypertension and heart conditions. The market is global in nature, meaning it spans across continents, catering to the medical needs of diverse populations. It includes a variety of ARBs, each with its unique properties and applications. The market is driven by various factors such as the increasing prevalence of cardiovascular diseases, advancements in medical technology, and the growing awareness about the importance of maintaining cardiovascular health.
Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan in the Global Angiotensin II Receptor Blockers Market:
Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, and Valsartan are some of the key products in the Global Angiotensin II Receptor Blockers Market. Each of these blockers has a unique mechanism of action and is used to treat different conditions. For instance, Azilsartan is often prescribed for hypertension, while Candesartan is commonly used to treat heart failure. Eprosartan and Irbesartan are known for their efficacy in treating diabetic nephropathy, a kidney complication of diabetes. Losartan, Olmesartan, and Telmisartan are widely used in the management of hypertension and heart failure. Valsartan, on the other hand, is used in treating heart failure and hypertension, and in reducing cardiovascular mortality following myocardial infarction. These blockers, with their diverse applications, form the backbone of the Global Angiotensin II Receptor Blockers Market.
Chronic Kidney Diseases, Heart Failure, Kidney Failure in Diabetes in the Global Angiotensin II Receptor Blockers Market:
The Global Angiotensin II Receptor Blockers Market plays a crucial role in managing chronic kidney diseases, heart failure, and kidney failure in diabetes. These conditions often require long-term management and treatment, making ARBs an essential part of the therapeutic regimen. For instance, in chronic kidney diseases, ARBs help in reducing proteinuria, a condition characterized by an abnormal amount of protein in the urine, a common symptom of kidney diseases. In heart failure, ARBs are used to reduce the workload on the heart, thereby improving the heart's efficiency. In the case of kidney failure in diabetes, ARBs are used to slow the progression of kidney damage. Thus, the Global Angiotensin II Receptor Blockers Market plays a pivotal role in managing these conditions, improving the quality of life for patients worldwide.
Global Angiotensin II Receptor Blockers Market Outlook:
Based on our analysis, the global medical devices market, which includes the Global Angiotensin II Receptor Blockers Market, is projected to reach a value of US$ 603 billion by 2023. This represents a significant growth, driven by a compound annual growth rate (CAGR) of 5% over the next six years. This growth can be attributed to various factors such as the increasing prevalence of chronic diseases, advancements in medical technology, and the growing global population. The market's growth is also fueled by the increasing demand for effective and efficient treatment modalities for various health conditions. Therefore, the future of the Global Angiotensin II Receptor Blockers Market looks promising, with ample opportunities for growth and development.
| Report Metric | Details |
| Report Name | Angiotensin II Receptor Blockers Market |
| Accounted market size in year | US$ 603 billion |
| CAGR | 5% |
| Base Year | year |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Merck & Co., AstraZeneca, Novartis, Teva, Bayer, GlaxoSmithKline, Sun Pharmaceutical, Mylan |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
